An innovative fixed-dose combination therapy that simultaneously treats type 2 diabetes and hypertension, with the potential to improve patient adherence and deliver synergistic benefits across related disease states.
The program is currently in the approval preparation stage.
01
Olmesartan
Angiotensin II receptor blocker (ARB) antihypertensive agent with superior blood pressure-lowering efficacy and a long duration of action.
02
Dapagliflozin
SGLT2 inhibitor with an insulin-independent mechanism of action, providing hypoglycemic effects along with weight reduction, blood pressure lowering, and cardiovascular benefits-particularly advantageous for obese or hypertensive patients.
